The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin
Open accessPublished version of a preprint
Abstract
Purpose: Defects in the homologous recombination (HR) repair pathway are of clinical interest due to sensitivity of HR-deficient cells to PARP inhibitors. We were interested in defining PARP vulnerability in patients with metastatic colorectal cancer (mCRC) carrying KRAS and BRAF mutations who display poor prognosis, have limited therapeutic options, and represent an unmet clinical need. Experimental Design: We tested colorectal cancer cell lines, patient-derived organoids (PDO), and patient-derived xenografts (PDX) enriched for KRAS and BRAF mutations for sensitivity to the PARP inhibitor olaparib, and the chemotherapeutic agents oxaliplatin and 5-fluorouracil (5-FU). Genomic profiles and DNA repair proficiency of colorectal cancer models were compared with pharmacologic response. Results: Thirteen of 99 (around 13%) colorectal cancer cell lines were highly sensitive to clinically active concentrations of olaparib and displayed functional deficiency in HR. Response to PARP blockade was positively correlated with sensitivity to oxaliplatin in colorectal cancer cell lines as well as patient-derived organoids. Treatment of PDXs with olaparib impaired tumor growth and maintenance therapy with PARP blockade after initial oxaliplatin response delayed disease progression in mice. Conclusions: These results indicate that a colorectal cancer subset characterized by poor prognosis and limited therapeutic options is vulnerable to PARP inhibition and suggest that PDO-based drug-screening assays can be used to identify patients with colorectal cancer likely to benefit from olaparib. As patients with mCRC almost invariably receive therapies based on oxaliplatin, “maintenance” treatment with PARP inhibitors warrants further clinical investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“For example, a subset of CRC cell lines enriched for KRAS or BRAF mutations were found to be highly sensitive to the PARP inhibitor olaparib and also displayed functional deficiency in homologous recombination [133].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [133]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · cited 11×
“Of note, 2 of 13 olaparib-sensitive cells displayed signature number three which is correlated with HR defects and BRCAness (47, 49).”
InfluentialMismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198 · cited 1×
“These tumors often display sensitivity to specific DNA damaging agents including platinum compounds and poly (ADP-ribose) polymerase (PARP) inhibitors (16-18).”
The consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170 · cited 1×
“Olaparib-sensitive cell lines were not enriched for any of the transcriptional consensus molecular subtypes (CMS) of colorectal cancer (45).”
BackgroundESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw235 · Cited by 3,421
Self-citationOlaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Moore, K., Colombo, N., Scambia, G., Kim, B.-G., Oaknin, A., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A., Sonke, G. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810858 · Cited by 2,870 · cited 1×
“We also found that sensitivity to oxaliplatin as determined in CRC models correlates with inhibition (21,25-27).”
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
Mirza, M. R., Monk, B. J., Herrstedt, J., Oza, A. M., Mahner, S., Redondo, A., Fabbro, M., Ledermann, J. A., Lorusso, D., Vergote, I., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611310 · Cited by 2,451 · cited 1×
“We noted that in ovarian cancers the clinical development of the PARP inhibitors has encountered similar difficulties in using genomic correlates to identify patients likely to respond (25, 54).”
BackgroundMaintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer
Golan, T., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., Park, J.-O., Hochhauser, D., Arnold, D., Oh, D.-Y., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903387 · Cited by 2,302
Landscape of somatic mutations in 560 breast cancer whole-genome sequences
Nik-Zainal, S., Davies, H., Staaf, J., Ramakrishna, M., Glodzik, D., Zou, X., Martincorena, I., Alexandrov, L. B., Martin, S., Wedge, D. C., et al. (2016) · Nature · doi:10.1038/nature17676 · Cited by 2,218 · cited 9×
“Of note, 2 of 13 olaparib-sensitive cells displayed signature number three which is correlated with HR defects and BRCAness (47, 49).”
Influential
Cited by
Genetic and biological hallmarks of colorectal cancer
Li, J., Ma, X., Chakravarti, D., Shalapour, S., & DePinho, R. A. (2021) · Genes & Development · doi:10.1101/gad.348226.120 · Cited by 573
“…to understand the genetic bases of response to therapies (Calon et al. 2015; Vlachogiannis et al. 2018; Ganesh et al. 2019; Ooft et al. 2019; Arena et al. 2020; Yao et al. 2020), profile genomic alterations (Bolhaqueiro et al. 2019) and intratumoral heterogeneity (Roerink et al. 2018; Bruun…”
BackgroundPatient-derived xenograft models in cancer therapy: technologies and applications
Liu, Y., Wu, W., Cai, C., Zhang, H., Shen, H., & Han, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01419-2 · Cited by 494
“As oxaliplatin is a common choice for such patients, this study provides a rationale for sequential treatment with oxaliplatin and olaparib.(182) With the aid of whole exome sequencing and transcriptome sequencing, PDX cohorts would facilitate the identification of biomarkers that can predict the drug sensitivity of p…”
BackgroundPrecision oncology in metastatic colorectal cancer — from biology to medicine
Di Nicolantonio, F., Vitiello, P. P., Marsoni, S., Siena, S., Tabernero, J., Trusolino, L., Bernards, R., & Bardelli, A. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00495-z · Cited by 239
Self-citationPromises and challenges of organoid-guided precision medicine
Bose, S., Clevers, H., & Shen, X. (2021) · Med · doi:10.1016/j.medj.2021.08.005 · Cited by 213
Schirris, Y., Gavves, E., Nederlof, I., Horlings, H. M., & Teuwen, J. (2022) · Medical Image Analysis · doi:10.1016/j.media.2022.102464 · Cited by 196
“(2020); Arena et al. (2020)) patients. Currently, the most common techniques for determining HRD or MSI are next-generation whole-genome and exome sequencing methods (Davies et al. (2017); Zhu et al. (2018)), targeted DNA sequencing methods using Polymerase Chain Reaction (Boland et al. (1998)), and immunohistochemist…”
BackgroundMethodInfluential
Metadata
- Authors
- Arena, S., Corti, G., Durinikova, E., Montone, M., Reilly, N. M., Russo, M., Lorenzato, A., Arcella, P., Lazzari, L., Rospo, G., Pagani, M., Cancelliere, C., Negrino, C., Isella, C., Bartolini, A., Cassingena, A., Amatu, A., Mauri, G., Sartore-Bianchi, A., Mittica, G., Medico, E., Marsoni, S., Linnebacher, M., Abrignani, S., Siena, S., Di Nicolantonio, F., & Bardelli, A.
- Affiliations
- Candiolo Cancer Institute (IT)
- Fondazione Piemontese per la Ricerca sul Cancro Onlus (IT)
- IFOM (IT)
- University of Milan (IT)
- Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda (IT)
- 7Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy.
- 1Candiolo Cancer Institute, FPO - IRCCS, Candiolo, Torino, Italy.
- University of Rostock (DE)
- Corresponding author
- Bardelli, Alberto
- ORCID
- Arena, Sabrina
- Corti, Giorgio
- Montone, Monica
- Reilly, Nicole M.
- Russo, Mariangela
- Lorenzato, Annalisa
- Arcella, Pamela
- Lazzari, Luca
- Rospo, Giuseppe
- Pagani, Massimiliano
- Negrino, Carola
- Isella, Claudio
- Bartolini, Alice
- Cassingena, Andrea
- Amatu, Alessio
- Mauri, Gianluca
- Sartore-Bianchi, Andrea
- Marsoni, Silvia
- Linnebacher, Michael
- Abrignani, Sergio
- Siena, Salvatore
- Di Nicolantonio, Federica
- Bardelli, Alberto
- Venue
- Clinical Cancer Research
- Published
- 2020-03-13
- Volume
- 26
- Issue
- 6
- Pages
- 1372-1384
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2996516440
- Cited by
- 115
- References
- 63
- Citations by year
- 2026: 6 · 2025: 14 · 2024: 12 · 2023: 16 · 2022: 22 · 2021: 38 · 2020: 7
- FWCI
- 7.06
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Funders
- AIRC (2018-ID. 21091, 2017-ID 20236, IG 2018-ID. 21923, IG no. 17707, IG no. 21407, 20685)
- European Community's Seventh Framework Programme (602901)
- H2020 (635342-2)
- IMI (115749)
- Ministero della Salute (NET 02352137)
- JTC (TRS-2015-00000060)
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- metastatic colorectal cancer, olaparib, PARP inhibitors, oxaliplatin, homologous recombination deficiency, KRAS mutation, BRAF mutation, 5-fluorouracil, patient-derived organoids, patient-derived xenografts, drug sensitivity, maintenance therapy, DNA repair
- MeSH terms
- Poly(ADP-ribose) Polymerase Inhibitors, Oxaliplatin, Animals, Antineoplastic Agents, Humans, Mutation, Phthalazines, Piperazines, Colorectal Neoplasms, Gene Expression Regulation, Neoplastic, Proto-Oncogene Proteins p21(ras), Mice, SCID, Mice, Inbred NOD, Treatment Outcome, Drug Resistance, Neoplasm, Xenograft Model Antitumor Assays, Cell Line, Tumor, Proto-Oncogene Proteins B-raf, Mice, Recombinational DNA Repair
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-19-2409
- The paper
- Arena, S., Corti, G., Durinikova, E., Montone, M., Reilly, N. M., Russo, M., Lorenzato, A., Arcella, P., Lazzari, L., Rospo, G., Pagani, M., Cancelliere, C., Negrino, C., Isella, C., Bartolini, A., Cassingena, A., Amatu, A., Mauri, G., Sartore-Bianchi, A., . . . Bardelli, A. (2020). A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-19-2409
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.